文献速递肝病

PREDICT研究揭示肝硬化急性失代偿的三种临床病程具有不同病理生理机制

The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
PubMed 文献 · J Hepatol · 2020-07-13

PREDICT研究为欧洲前瞻性观察研究,纳入1071例肝硬化急性失代偿患者,随访3个月并记录1年结局,识别出前慢加急性肝衰竭(pre-ACLF)、不稳定失代偿肝硬化(UDC)和稳定失代偿肝硬化(SDC)三组,三组在全身炎症程度与病程及重度门静脉高压替代指标上差异显著。

要点

  • pre-ACLF组(n=218)3个月和1年死亡率分别为53.7%和67.4%。
  • UDC组(n=233)需≥1次再入院但未发生ACLF,3个月和1年死亡率分别为21.0%和35.6%。
  • SDC组(n=620)未再入院且未发生ACLF,1年死亡率仅9.5%。

核心结论

  • 不伴ACLF的急性失代偿是异质性疾病,具有3种不同临床病程和2种主要病理生理机制:全身炎症和门静脉高压。
  • 预测ACLF的发生仍是未来重大挑战。

研究设计与样本

  • PREDICT研究为欧洲前瞻性观察研究,纳入1071例肝硬化急性失代偿患者。
  • 收集入组前3个月预设详细信息及入组时临床和实验室数据,密切随访3个月,并记录1年结局(肝移植和死亡)。

主要发现

  • pre-ACLF组(n=218)发生ACLF,3个月和1年死亡率分别为53.7%和67.4%。
  • UDC组(n=233)需≥1次再入院但未发生ACLF,3个月和1年死亡率分别为21.0%和35.6%。
  • SDC组(n=620)未再入院且未发生ACLF,1年死亡率仅9.5%。
  • 三组全身炎症等级和病程显著不同:pre-ACLF入组时高级别且随访期间加重;UDC入组时低级别且后续稳定;SDC入组时低级别且后续改善。
  • 研究全程重度门静脉高压替代指标患病率:UDC高 vs pre-ACLF和SDC低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF. METHODS: A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded. RESULTS: Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC). CONCLUSIONS: Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS. GOV NUMBER: NCT03056612. LAY SUMMARY: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020. PMID: 32673741. doi:10.1016/j.jhep.2020.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。